Clinical Trial Update: A Study of JNJ-61393215 in the Treatment of Depression [Phase 2]

View source ↗

Summary

A Phase 2 trial of JNJ-61393215 for major depressive disorder with anxious distress has completed, and its results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder with Anxious Distress

Drugs mentioned

• JNJ-61393215

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Major Depressive Disorder With Anxious Distress | Phase 2 | Status: COMPLETED | Results posted: 2022-09-29